Stemline Therapeutics, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: New York NY United States (2003)
Status: Acquired by Menarini Group (2020)

Organization Overview

First Clinical Trial
2014
NCT02078648
First Marketed Drug
2012
tagraxofusp-erzs (elzonris)
First NDA Approval
2018
tagraxofusp-erzs (elzonris)
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

STEMLINE THERAP | STEMLINE THERAPEEUTICS INC | Stemline Therapeutics, Inc. | STEMLINE THERAPEUTICS INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Glioma (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Preleukemia (Phase 1)

Primary Myelofibrosis (Phase 2)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 10